samedan logo
 
 
 
spacer
home > pmps > autumn 2020 > the automation of change
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Automation of Change

Medication non-adherence among patients is a complex issue, and it remains a pressing matter for the NHS. Figures suggest that in the EU alone nearly 200,000 deaths occur each year due to missed doses of medication and that 500 million is the yearly cost to the NHS of a patient not taking their medication properly (1-2). It is clear that patient adherence levels need to improve drastically to improve patient outcomes and lessen the burden on the health service.

Non-adherence within primary care can be a particular problem as it is often the patient or carer who is responsible for administering medication after receiving a prescription from a healthcare professional. One of the many ways to support adherence is creating a culture of education fostered around patient adherence to support the public in this role. Community pharmacists are ideally placed to do this but they need more time and resources to build better interpersonal relationships with members of the public to help them understand their medication regimes. Industry pioneers see technology as an innovative and attainable solution to support community pharmacies in this role. Automation in pharmacy will free up pharmacists' time, allowing them to focus more on patient care.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cyrus Hodivala is the Medication Adherence Sales Director at Omnicell. Founded in 1992, Omnicell is a leading provider of medication and supply management solutions to the global healthcare market. The company specialises in improving patient safety from hospital to home, and using better management of supplies and medications to improve standards of care by allowing clinicians to spend more time with their patients.
spacer
Cyrus Hodivala
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement